4D Molecular Therapeutics (FDMT) Equity Ratio (2019 - 2025)
Historic Equity Ratio for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to 0.87.
- 4D Molecular Therapeutics' Equity Ratio fell 493.26% to 0.87 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.87, marking a year-over-year decrease of 493.26%. This contributed to the annual value of 0.91 for FY2024, which is 60.75% up from last year.
- Latest data reveals that 4D Molecular Therapeutics reported Equity Ratio of 0.87 as of Q3 2025, which was down 493.26% from 0.89 recorded in Q2 2025.
- Over the past 5 years, 4D Molecular Therapeutics' Equity Ratio peaked at 0.95 during Q1 2024, and registered a low of 0.87 during Q3 2025.
- In the last 5 years, 4D Molecular Therapeutics' Equity Ratio had a median value of 0.91 in 2025 and averaged 0.91.
- In the last 5 years, 4D Molecular Therapeutics' Equity Ratio surged by 642.94% in 2024 and then plummeted by 633.7% in 2025.
- 4D Molecular Therapeutics' Equity Ratio (Quarter) stood at 0.9 in 2021, then dropped by 2.13% to 0.88 in 2022, then increased by 2.51% to 0.91 in 2023, then rose by 0.61% to 0.91 in 2024, then decreased by 4.49% to 0.87 in 2025.
- Its Equity Ratio was 0.87 in Q3 2025, compared to 0.89 in Q2 2025 and 0.91 in Q1 2025.